Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The newly approved use of an
Atovaquone
(
Mepron
) suspension for treating mild to moderate Pneumocystis carinii (
PCP
) in patients unable to tolerate trimethoprim-sulfamethoxazole (TMP-SMX), has shown that it is twice as bioavailable compared with the previously licensed tablet formulation. However,
Atovaquone
use has produced more deaths than TMP-SMX, a problem that may in part be due to its lack of a broad antibacterial spectrum.
...
PMID:Atovaquone (Mepron) suspension approved by FDA. Food and Drug Administration. 1136 54
Glaxo Wellcome, makers of atovaquone (
Mepron
), has announced that the Food and Drug Administration (FDA) has cleared a new suspension formulation of the drug that produces better results than the tablets. The suspension is indicated for the treatment of mild to moderate cases of
PCP
in patients who are intolerant to other therapies.
...
PMID:Liquid atovaquone (Mepron) for PCP. 1136 75
